loading

Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie

pulisher
Nov 19, 2024

Sagimet Biosciences participates ik,on No - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences keeps stock target with Buy rating on phase 3 program - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences Presents Clinical Denifanstat and - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDThe Liver Meeting® 2024 - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet's Denifanstat Shows 49% Fibrosis Improvement in Phase 2b MASH Trial | SGMT Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance

Nov 18, 2024
pulisher
Nov 16, 2024

Sagimet Biosciences (NASDAQ:SGMT) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Steven Cohen's Strategic Acquisition in Sagimet Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Hillhouse Capital Management's Strategic Reduction in Sagimet Bi - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Baker Bros. Advisors LP Increases Stake in Sagimet Biosciences I - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $24.00 Consensus Price Target from Analysts - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences Advances MASH Treatment with Denifanstat - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet: More Than Just A MASH Drug Development Biotech (NASDAQ:SGMT) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences reports Q3 EPS (45c) vs (35c) last year - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 13, 2024

Ascletis Completes Enrollment of Phase III Trial of ASC40 Once-Daily Oral Tablet for Treatment of Acne - Marketscreener.com

Nov 13, 2024
pulisher
Nov 12, 2024

UBS says Sagimet stock could steal the MASH spotlight from injectables - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Sagimet stock draws buy at UBS on MASH(SGMT:NASDAQ) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

SGMTSagimet Biosciences Inc. Series A Latest Stock News & Market Updates - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) Price Target at $24.00 - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS Group - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Sagimet Biosciences initiated with a Buy at UBS - TipRanks

Nov 12, 2024
pulisher
Nov 10, 2024

Sagimet Biosciences Insiders Benefit From Selling Stock At US$3.10 - Simply Wall St

Nov 10, 2024
pulisher
Nov 08, 2024

Trend Tracker for (SGMT) - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 07, 2024

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference - The Manila Times

Nov 07, 2024
pulisher
Nov 04, 2024

Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD - Liver Disease News

Nov 04, 2024
pulisher
Oct 31, 2024

HC Wainwright Reaffirms "Buy" Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Sagimet’s denifanstat enters Phase III trials for MASH treatment - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of End-Of-Phase 2 Interactions with Fda on the Development of Denifanstat for Mash - Marketscreener.com

Oct 29, 2024
pulisher
Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 - The Manila Times

Oct 29, 2024
pulisher
Oct 28, 2024

(SGMT) Technical Data - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 26, 2024

Sagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Update - MarketBeat

Oct 26, 2024
pulisher
Oct 18, 2024

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha

Oct 18, 2024
pulisher
Oct 18, 2024

(SGMT) Investment Analysis and Advice - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 16, 2024

There is no way Sagimet Biosciences Inc (SGMT) can keep these numbers up - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

Market Highlights: Sagimet Biosciences Inc (SGMT) Ends on a Low Note at 5.13 - The Dwinnex

Oct 16, 2024
pulisher
Oct 16, 2024

Sagimet Biosciences Announces Upcoming Presentations at AASLDThe Liver Meeting® 2024 - GlobeNewswire

Oct 16, 2024
pulisher
Oct 15, 2024

How to interpret Sagimet Biosciences Inc (SGMT)’s stock chart patterns - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Sagimet Biosciences Inc’s Shares Reel: 42.19% Quarterly Revenue Decline Amid 167.12M Market Cap - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

SGMT (Sagimet Biosciences Inc) may reap gains as insiders became active recently - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in the Lancet Gastroenterology and Hepatology - Marketscreener.com

Oct 14, 2024
pulisher
Oct 11, 2024

Sagimet Gains on Latest Numbers - Baystreet.ca

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet's denifanstat shows promise in Phase 2b MASH trial - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet's denifanstat shows promise in Phase 2b MASH trial By Investing.com - Investing.com UK

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial - The Bakersfield Californian

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from - GlobeNewswire

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - StockTitan

Oct 11, 2024
pulisher
Oct 10, 2024

Sagimet Biosciences Inc (SGMT) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

Sagimet Biosciences Inc [SGMT] Shares Fall Approximately -47.47% Over the Year - Knox Daily

Oct 10, 2024
pulisher
Oct 09, 2024

Financial Metrics Check: Sagimet Biosciences Inc (SGMT)’s Ratios for Trailing Twelve Months - The Dwinnex

Oct 09, 2024
pulisher
Oct 08, 2024

How does Sagimet Biosciences Inc (SGMT) change from a tortoise to a hare? - SETE News

Oct 08, 2024
pulisher
Oct 08, 2024

Sagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Renaissance Technologies LLC - MarketBeat

Oct 08, 2024
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):